CDK9-IN-14 structure
|
Common Name | CDK9-IN-14 | ||
---|---|---|---|---|
CAS Number | 2650640-17-6 | Molecular Weight | 419.42 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C21H23F2N3O4 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of CDK9-IN-14CDK9-IN-14 is a potent and selective CDK9 inhibitor with IC50 of 6.92 nM. CDK9-IN-14 has a relatively strong inhibitory effect on MV4;11 cells and in vivo tumor models, and has a good selectivity and a low toxicity and few side effects[1]. |
Name | CDK9-IN-14 |
---|
Description | CDK9-IN-14 is a potent and selective CDK9 inhibitor with IC50 of 6.92 nM. CDK9-IN-14 has a relatively strong inhibitory effect on MV4;11 cells and in vivo tumor models, and has a good selectivity and a low toxicity and few side effects[1]. |
---|---|
Related Catalog | |
Target |
CDK9:6.92 nM (IC50) |
In Vitro | CDK9-IN-14 (0-1000 nM) has strong inhibitory effect in MV4;11 cells with IC50 = 34 nM[1]. |
In Vivo | CDK9-IN-14 (5 mg/kg; p.o., qd, for 9 days) exhibits significant anti-tumor effect with tumor growth inhibition (TGI) value of 58%[1]. Animal Model: Female Nu/Nu mice (6-8 weeks old, 18-22 g, injected with HL-60 cells)[1] Dosage: 5 mg/kg Administration: p.o., qd, for 9 days Result: Exhibited significant anti-tumor effect with tumor growth inhibition (TGI) value of 58%. |
References |
[1]. WANG Zhenyu. Compound as cyclin-dependent kinase 9 inhibitor and use thereof. WO2021115335A1 |
Molecular Formula | C21H23F2N3O4 |
---|---|
Molecular Weight | 419.42 |